{"id":251436,"date":"2021-10-11T00:00:00","date_gmt":"2021-10-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0127-biopharma-pemphigus-vulgaris-epidemiology-europe\/"},"modified":"2026-05-03T11:21:18","modified_gmt":"2026-05-03T11:21:18","slug":"epidim0127-biopharma-pemphigus-vulgaris-epidemiology-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0127-biopharma-pemphigus-vulgaris-epidemiology-europe\/","title":{"rendered":"Pemphigus Vulgaris &#8211; Epidemiology &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland, Portugal, Sweden, and Switzerland). We report both the diagnosed incidence and prevalence of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How many people in each of the major European pharmaceutical markets have been formally diagnosed with <abbr title=\"pemphigus vulgaris\">PV<\/abbr>; how many are newly diagnosed each year?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts three patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases by severity.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251436","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251436\/revisions"}],"predecessor-version":[{"id":283872,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251436\/revisions\/283872"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}